Company Overview
Oriola Oyj is a Finnish public company specializing in pharmaceuticals and healthcare products. With its headquarters in Espoo, Finland, the company has established itself as a leading player in the Nordic market. Oriola's primary mission is to improve people's health and well-being through innovative products and services.
The company's core values are built around its commitment to customer satisfaction, operational excellence, and sustainable growth. By prioritizing these principles, Oriola aims to create long-term value for its stakeholders while maintaining a strong reputation in the industry.
Key Products/Services
Oriola offers a wide range of pharmaceuticals and healthcare products, including prescription medications, over-the-counter remedies, and medical devices. The company's product portfolio is designed to cater to various customer needs, from general health and wellness to specialized treatments for chronic conditions.
One of Oriola's key strengths lies in its ability to provide high-quality products with a strong focus on patient safety and efficacy. The company's products are developed in partnership with leading pharmaceutical companies and are manufactured according to strict quality standards.
Benefits
Oriola's products offer numerous benefits, including improved health outcomes, enhanced quality of life, and increased convenience for customers. By leveraging its extensive network of distributors and pharmacies, the company ensures that its products reach a wide range of customers across the Nordic region.
Furthermore, Oriola's commitment to innovation and R&D enables it to stay at the forefront of emerging trends in healthcare. This allows the company to develop new products and services that address evolving customer needs and preferences.
Business Model
Oriola operates primarily through its distribution and wholesale segments, which cater to various customer segments, including pharmacies, hospitals, and healthcare professionals. The company's business model is designed to balance profitability with customer satisfaction and operational efficiency.
By focusing on high-margin products and services, Oriola aims to generate strong revenue growth while maintaining a competitive market position.
Valuation
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Number of Shares (million) | 181.5 | 181.5 | 181.5 | 185.3 | 185.3 | 185.3 | 185.3 |
| Target Valuation (MEur) | 544.9 | 534.7 | 758.3 | 757.4 | 617.9 | 351.1 | 351.1 |
| Targer Price | 3.0 | 2.95 | 4.18 | 4.09 | 3.33 | 1.89 | 1.89 |
| Potential, % | 72.5 | 170.7 | 369.5 | 255.4 | 274.7 | 112.9 | 112.9 |
| Recommendation | Buy | Buy | Buy | Buy | Buy | Buy | Buy |
| MCAP (MEur) | 315.8 | 197.5 | 161.5 | 213.1 | 164.9 | 164.9 | 164.9 |
| Price | 1.74 | 1.09 | 0.89 | 1.15 | 0.89 | 0.89 | 0.89 |
| EV | 292.0 | 177.0 | 124.0 | 131.0 | 122.0 | 131.0 | 127.0 |
| P/S | 0.21 | 0.13 | 0.1 | 0.11 | 0.8 | 0.8 | 0.75 |
| EV/S | 0.19 | 0.12 | 0.07 | 0.07 | 0.59 | 0.63 | 0.57 |
| EV/EBIT | 38.43 | -34.01 | 9.13 | 52.41 | -243.18 | -10.82 | -12.81 |
| P/E | 65.79 | -9.54 | -43.65 | -25.37 | -28.54 | -17.06 | -20.85 |
| P/B | 1.4 | 1.15 | 1.21 | 2.11 | 1.92 | 2.17 | 2.42 |
| P/OCF | 4.05 | 20.57 | 4.17 | 3.55 | -7.64 | -41.13 | 18.17 |
| EV/OCF | 3.75 | 18.42 | 3.21 | 2.18 | -5.63 | -32.59 | 13.95 |
| P/FCF | 3.9 | 32.37 | 4.5 | 3.55 | -5.19 | -18.16 | 41.18 |
| EV/FCF | 3.61 | 28.99 | 3.46 | 2.18 | -3.83 | -14.38 | 31.63 |
Income Statement
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Revenue | 1515.4 | 1493.9 | 1679.6 | 1906.3 | 205.2 | 207.2 | 220.8 |
| Rev. Growth, % | 4.4 | -1.4 | 12.4 | 13.5 | -89.2 | 1.0 | 6.6 |
| Ebit | 7.6 | -5.2 | 13.6 | 2.5 | -0.5 | -12.1 | -9.9 |
| Ebit Growth, % | -29.6 | -168.4 | 361.5 | -81.6 | -120.0 | -2320.0 | 18.2 |
| Ebit, % | 0.5 | -0.3 | 0.8 | 0.1 | -0.2 | -5.8 | -4.5 |
| Profit | 4.8 | -20.7 | -3.7 | -8.4 | -5.8 | -9.7 | -7.9 |
| EPS | 0.03 | -0.11 | -0.02 | -0.05 | -0.03 | -0.05 | -0.04 |
| Profit Growth, % | -44.2 | -531.2 | 82.1 | -127.0 | 31.0 | -67.2 | 18.6 |
| Profit, % | 0.3 | -1.4 | -0.2 | -0.4 | -2.8 | -4.7 | -3.6 |
Balance Sheet
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Inventory | 148.5 | 162.9 | 176.3 | 188.5 | 6.9 | 7.2 | 6.8 |
| Acc. Receivable | 226.8 | 259.5 | 247.1 | 311.7 | 358.5 | 391.2 | 387.9 |
| Cash | 160.6 | 138.4 | 113.5 | 152.2 | 120.6 | 111.6 | 115.6 |
| Equity | 225.6 | 171.3 | 133.4 | 100.8 | 85.8 | 76.2 | 68.2 |
| ROE, % | 2.1 | -12.1 | -2.8 | -8.3 | -6.8 | -12.7 | -11.6 |
| ROCE, % | 2.1 | -1.8 | 6.5 | 1.5 | -0.3 | -7.9 | -6.8 |
| Net Debt | -23.7 | -20.6 | -37.4 | -82.1 | -43.4 | -34.3 | -38.3 |
| Gearing, % | -10.5 | -12.0 | -28.0 | -81.4 | -50.5 | -45.0 | -56.1 |
| Equity ratio, % | 23.5 | 18.3 | 15.2 | 10.7 | 10.9 | 8.5 | 8.4 |
| Acc. Payable | 557.3 | 607.5 | 626.2 | 725.7 | 531.7 | 502.1 | 528.7 |
| Total Assets | 960.9 | 934.7 | 875.6 | 946.1 | 789.5 | 895.1 | 811.1 |
| ROA, % | 0.5 | -2.2 | -0.4 | -0.9 | -0.7 | -1.1 | -1.0 |
Cash Flow
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 77.9 | 9.6 | 38.7 | 60.0 | -21.6 | -4.0 | 9.1 |
| Investment Cash Flow | 3.0 | -3.5 | -2.8 | 0.0 | -10.2 | -5.1 | -5.1 |
| Free Cash Flow | 80.9 | 6.1 | 35.9 | 60.0 | -31.8 | -9.1 | 4.0 |
| OCF/CAPEX | 0.0 | 2.74 | 13.82 | 0.0 | 0.0 | 0.0 | 1.79 |
| Financial Cash Flow | -29.3 | -28.3 | -60.7 | -21.7 | 0.2 | 0.0 | 0.0 |
Disclaimer
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.
Contact: quant@quantfactory.eu